Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 584,609 shares, a growth of 823.5% from the July 30th total of 63,307 shares. Currently, 9.0% of the company’s stock are sold short. Based on an average daily volume of 38,485,659 shares, the days-to-cover ratio is presently 0.0 days.

Creative Medical Technology Stock Performance

Shares of Creative Medical Technology stock traded up $0.03 on Tuesday, reaching $1.24. 167,613 shares of the company were exchanged, compared to its average volume of 3,796,424. The company’s 50-day moving average is $1.16 and its two-hundred day moving average is $1.76. The firm has a market cap of $8.17 million, a price-to-earnings ratio of -0.60 and a beta of 1.95. Creative Medical Technology has a 1-year low of $0.62 and a 1-year high of $6.25.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, sell-side analysts forecast that Creative Medical Technology will post -1.18 earnings per share for the current year.

Wall Street Analyst Weigh In

CELZ has been the topic of several analyst reports. Roth Capital restated a “buy” rating on shares of Creative Medical Technology in a report on Thursday, August 20th. Weiss Ratings raised shares of Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, Wall Street Zen upgraded shares of Creative Medical Technology to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Clear Harbor Asset Management LLC acquired a new position in shares of Creative Medical Technology in the 2nd quarter worth $192,000. Jane Street Group LLC purchased a new stake in shares of Creative Medical Technology during the fourth quarter valued at $59,000. Finally, Seros Financial LLC purchased a new stake in shares of Creative Medical Technology during the second quarter valued at $53,000. 1.42% of the stock is owned by institutional investors and hedge funds.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.